288 related articles for article (PubMed ID: 31694342)
1. Non-Coding RNA and Tumor Development in Neurofibromatosis Type 1:
Tritto V; Ferrari L; Esposito S; Zuccotti P; Bianchessi D; Natacci F; Saletti V; Eoli M; Riva P
Genes (Basel); 2019 Nov; 10(11):. PubMed ID: 31694342
[TBL] [Abstract][Full Text] [Related]
2. Role of noncoding RNA ANRIL in genesis of plexiform neurofibromas in neurofibromatosis type 1.
Pasmant E; Sabbagh A; Masliah-Planchon J; Ortonne N; Laurendeau I; Melin L; Ferkal S; Hernandez L; Leroy K; Valeyrie-Allanore L; Parfait B; Vidaud D; Bièche I; Lantieri L; Wolkenstein P; Vidaud M;
J Natl Cancer Inst; 2011 Nov; 103(22):1713-22. PubMed ID: 22034633
[TBL] [Abstract][Full Text] [Related]
3. Non-coding RNA ANRIL and the number of plexiform neurofibromas in patients with NF1 microdeletions.
Mußotter T; Kluwe L; Högel J; Nguyen R; Cooper DN; Mautner VF; Kehrer-Sawatzki H
BMC Med Genet; 2012 Oct; 13():98. PubMed ID: 23101500
[TBL] [Abstract][Full Text] [Related]
4. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
Gottfried ON; Viskochil DH; Couldwell WT
Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
[TBL] [Abstract][Full Text] [Related]
5. Genotype-phenotype associations in neurofibromatosis type 1 (NF1): an increased risk of tumor complications in patients with NF1 splice-site mutations?
Alkindy A; Chuzhanova N; Kini U; Cooper DN; Upadhyaya M
Hum Genomics; 2012 Aug; 6(1):12. PubMed ID: 23244495
[TBL] [Abstract][Full Text] [Related]
6. Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1.
Rasmussen SA; Overman J; Thomson SA; Colman SD; Abernathy CR; Trimpert RE; Moose R; Virdi G; Roux K; Bauer M; Rojiani AM; Maria BL; Muir D; Wallace MR
Genes Chromosomes Cancer; 2000 Aug; 28(4):425-31. PubMed ID: 10862051
[TBL] [Abstract][Full Text] [Related]
7. MicroRNAome profiling in benign and malignant neurofibromatosis type 1-associated nerve sheath tumors: evidences of PTEN pathway alterations in early NF1 tumorigenesis.
Masliah-Planchon J; Pasmant E; Luscan A; Laurendeau I; Ortonne N; Hivelin M; Varin J; Valeyrie-Allanore L; Dumaine V; Lantieri L; Leroy K; Parfait B; Wolkenstein P; Vidaud M; Vidaud D; Bièche I
BMC Genomics; 2013 Jul; 14():473. PubMed ID: 23848554
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the somatic mutational spectrum of the neurofibromatosis type 1 (NF1) gene in neurofibromatosis patients with benign and malignant tumors.
Upadhyaya M; Han S; Consoli C; Majounie E; Horan M; Thomas NS; Potts C; Griffiths S; Ruggieri M; von Deimling A; Cooper DN
Hum Mutat; 2004 Feb; 23(2):134-146. PubMed ID: 14722917
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in neurofibromatosis type 1.
Arun D; Gutmann DH
Curr Opin Neurol; 2004 Apr; 17(2):101-5. PubMed ID: 15021234
[TBL] [Abstract][Full Text] [Related]
10. The role of miRNAs and lncRNAs in neurofibromatosis type 1.
Khosravi T; Oladnabi M
J Cell Biochem; 2023 Jan; 124(1):17-30. PubMed ID: 36345594
[TBL] [Abstract][Full Text] [Related]
11. An emerging role for microRNAs in NF1 tumorigenesis.
Sedani A; Cooper DN; Upadhyaya M
Hum Genomics; 2012 Nov; 6(1):23. PubMed ID: 23158014
[TBL] [Abstract][Full Text] [Related]
12. Peripheral nerve tumors in neurofibromatosis 1: An overview on management and indications for surgical treatment in our experience.
Garozzo D
Neurol India; 2019; 67(Supplement):S38-S44. PubMed ID: 30688231
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of loss of heterozygosity in neurofibromatosis type 1-associated plexiform neurofibromas.
Steinmann K; Kluwe L; Friedrich RE; Mautner VF; Cooper DN; Kehrer-Sawatzki H
J Invest Dermatol; 2009 Mar; 129(3):615-21. PubMed ID: 18800150
[TBL] [Abstract][Full Text] [Related]
14. Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis.
Upadhyaya M; Spurlock G; Thomas L; Thomas NS; Richards M; Mautner VF; Cooper DN; Guha A; Yan J
Hum Mutat; 2012 Apr; 33(4):763-76. PubMed ID: 22331697
[TBL] [Abstract][Full Text] [Related]
15. Neurological malignancies in neurofibromatosis type 1.
Eoli M; Saletti V; Finocchiaro G
Curr Opin Oncol; 2019 Nov; 31(6):554-561. PubMed ID: 31436563
[TBL] [Abstract][Full Text] [Related]
16. Recurrent mutations in the NF1 gene are common among neurofibromatosis type 1 patients.
Ars E; Kruyer H; Morell M; Pros E; Serra E; Ravella A; Estivill X; Lázaro C
J Med Genet; 2003 Jun; 40(6):e82. PubMed ID: 12807981
[No Abstract] [Full Text] [Related]
17. Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1.
Warrington NM; Woerner BM; Daginakatte GC; Dasgupta B; Perry A; Gutmann DH; Rubin JB
Cancer Res; 2007 Sep; 67(18):8588-95. PubMed ID: 17875698
[TBL] [Abstract][Full Text] [Related]
18. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
19. The impact of coexisting genetic mutations on murine optic glioma biology.
Kaul A; Toonen JA; Gianino SM; Gutmann DH
Neuro Oncol; 2015 May; 17(5):670-7. PubMed ID: 25246427
[TBL] [Abstract][Full Text] [Related]
20. A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations.
Sharif S; Upadhyaya M; Ferner R; Majounie E; Shenton A; Baser M; Thakker N; Evans DG
J Med Genet; 2011 Apr; 48(4):256-60. PubMed ID: 21278392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
